MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/qad.0b013e328310e04f

Медицинская библиотека · AIDS (London, England) · 2008

Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.

Cozzi-Lepri Alessandro, Phillips Andrew N, Clotet Bonaventura, Mocroft Amanda, Ruiz Lidia, Kirk Ole, Lazzarin Adriano, Wiercinska-Drapalo Alicja, Karlsson Anders, Lundgren Jens D, EuroSIDA Study Group

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE(S): To investigate the relationship between detection of HIV drug resistance by 2 years from starting antiretroviral therapy and the subsequent risk of progression to AIDS and death.

DESIGN

Virological failure was defined as experiencing two consecutive viral loads of more than 400 copies/ml in the time window between 0.5 and 2 years from starting antiretroviral therapy (baseline). Patients were grouped according to evidence of virological failure and whether there was detection of the International AIDS Society resistance mutations to one, two or three drug classes in the time window.

METHODS

Standard survival analysis using Kaplan-Meier curves and Cox proportional hazards regression model with time-fixed covariates defined at baseline was employed.

RESULTS

We studied 8229 patients in EuroSIDA who started antiretroviral therapy and who had at least 2 years of clinical follow-up. We observed 829 AIDS events and 571 deaths during 38,814 person-years of follow-up resulting in an overall incidence of new AIDS and death of 3.6 per 100 person-years of follow-up [95% confidence interval (CI):3.4-3.8]. By 96 months from baseline, the proportion of patients with a new AIDS diagnosis or death was 20.3% (95% CI:17.7-22.9) in patients with no evidence of virological failure and 53% (39.3-66.7) in those with virological failure and mutations to three drug classes (P = 0.0001). An almost two-fold difference in risk was confirmed in the multivariable analysis (adjusted relative hazard = 1.8, 95% CI:1.2-2.7, P = 0.005).

CONCLUSION

Although this study shows an association between the detection of resistance at failure and risk of clinical progression, further research is needed to clarify whether resistance reflects poor adherence or directly increases the risk of clinical events via exhaustion of drug options.

Для цитирования: Cozzi-Lepri Alessandro, Phillips Andrew N, Clotet Bonaventura, Mocroft Amanda, Ruiz Lidia, Kirk Ole, Lazzarin Adriano, Wiercinska-Drapalo Alicja, Karlsson Anders, Lundgren Jens D, EuroSIDA Study Group. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.. AIDS (London, England). 2008. DOI: 10.1097/qad.0b013e328310e04f.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.